Global biopharma R&D productivity rebounded in 2023, according to a new report.
There were higher composite success rates enabled by industry-wide and regulator adoption of data and tech-driven innovation, including novel trial design, optimized biomarker use, and digital and decentralized trial methodologies, the analysis found.
This rebound occurred while clinical trial starts and funding returned to pre-pandemic levels, according to the report, Global Trends in R&D 2024: Activity, Productivity, and Enablers, released by the IQVIA Institute for Human Data Science.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze